Flexion Therapeutics Inc (NASDAQ:FLXN) Expected to Post Quarterly Sales of $9.50 Million

Brokerages forecast that Flexion Therapeutics Inc (NASDAQ:FLXN) will announce $9.50 million in sales for the current quarter, according to Zacks Investment Research. Three analysts have provided estimates for Flexion Therapeutics’ earnings. The highest sales estimate is $11.80 million and the lowest is $8.00 million. Flexion Therapeutics reported sales of $16.95 million during the same quarter last year, which indicates a negative year-over-year growth rate of 44%. The business is scheduled to issue its next earnings report on Tuesday, August 4th.

On average, analysts expect that Flexion Therapeutics will report full-year sales of $73.78 million for the current fiscal year, with estimates ranging from $65.13 million to $84.80 million. For the next financial year, analysts expect that the company will report sales of $164.13 million, with estimates ranging from $150.00 million to $185.60 million. Zacks’ sales calculations are an average based on a survey of sell-side research firms that follow Flexion Therapeutics.

Flexion Therapeutics (NASDAQ:FLXN) last released its quarterly earnings results on Thursday, May 7th. The specialty pharmaceutical company reported ($0.95) earnings per share for the quarter, beating analysts’ consensus estimates of ($1.00) by $0.05. Flexion Therapeutics had a negative net margin of 175.76% and a negative return on equity of 592.50%. The business had revenue of $20.13 million for the quarter, compared to analysts’ expectations of $18.45 million.

A number of analysts recently commented on FLXN shares. Northland Securities started coverage on shares of Flexion Therapeutics in a research note on Tuesday, June 2nd. They issued a “buy” rating and a $35.00 target price for the company. HC Wainwright assumed coverage on shares of Flexion Therapeutics in a research report on Thursday, June 25th. They set a “buy” rating and a $25.00 price target for the company. ValuEngine raised shares of Flexion Therapeutics from a “hold” rating to a “buy” rating in a research report on Thursday, April 2nd. Raymond James reduced their price target on shares of Flexion Therapeutics from $23.00 to $20.00 and set a “strong-buy” rating for the company in a research report on Monday, April 27th. Finally, Needham & Company LLC cut their target price on shares of Flexion Therapeutics from $30.00 to $20.00 and set a “buy” rating for the company in a report on Friday, May 8th. One analyst has rated the stock with a hold rating, eleven have given a buy rating and one has assigned a strong buy rating to the company’s stock. The company has an average rating of “Buy” and an average target price of $22.64.

Shares of NASDAQ:FLXN traded down $0.17 during trading on Friday, reaching $11.99. The stock had a trading volume of 316,500 shares, compared to its average volume of 648,193. The firm’s 50-day simple moving average is $12.00 and its 200 day simple moving average is $13.17. Flexion Therapeutics has a one year low of $5.01 and a one year high of $22.98.

In other Flexion Therapeutics news, CEO Michael D. Clayman purchased 10,256 shares of the business’s stock in a transaction on Tuesday, May 26th. The shares were bought at an average cost of $9.75 per share, for a total transaction of $99,996.00. Following the completion of the purchase, the chief executive officer now directly owns 64,957 shares of the company’s stock, valued at $633,330.75. The transaction was disclosed in a document filed with the SEC, which can be accessed through this hyperlink. 17.03% of the stock is owned by corporate insiders.

Several hedge funds have recently bought and sold shares of the company. Moody National Bank Trust Division acquired a new stake in shares of Flexion Therapeutics in the second quarter valued at approximately $5,067,000. AQR Capital Management LLC purchased a new position in Flexion Therapeutics in the first quarter worth $101,000. Squarepoint Ops LLC raised its position in Flexion Therapeutics by 5.1% in the first quarter. Squarepoint Ops LLC now owns 41,043 shares of the specialty pharmaceutical company’s stock worth $323,000 after acquiring an additional 1,987 shares in the last quarter. Paloma Partners Management Co purchased a new position in Flexion Therapeutics in the first quarter worth $92,000. Finally, Invesco Ltd. raised its position in Flexion Therapeutics by 31.3% in the first quarter. Invesco Ltd. now owns 97,032 shares of the specialty pharmaceutical company’s stock worth $764,000 after acquiring an additional 23,129 shares in the last quarter. 83.08% of the stock is owned by institutional investors and hedge funds.

Flexion Therapeutics Company Profile

Flexion Therapeutics, Inc, a biopharmaceutical company, focuses on the discovery, development, and commercialization of anti-inflammatory and analgesic therapies for the treatment of patients with musculoskeletal conditions. It offers ZILRETTA, an intra-articular injection for the management of osteoarthritis (OA) pain of the knee in the United States.

Read More: What are the most popular ETFs

Get a free copy of the Zacks research report on Flexion Therapeutics (FLXN)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Receive News & Ratings for Flexion Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Flexion Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.



Comments


share news on Facebook
tweet this investment news
share on linkedin
share on StockTwits
share on reddit